» Articles » PMID: 35834927

Synchronous Breast Cancer and Non-Hodgkin Lymphoma: A Case Report

Overview
Specialty General Surgery
Date 2022 Jul 14
PMID 35834927
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Among women, breast cancer (BC) is the most prevalent type of cancer and the top cause of cancer deaths. Although non-Hodgkin lymphoma (NHL) is the most prevalent hematological cancer, it is rarely reported synchronous with BC. Moreover, which malignancy appears first can rarely be explained because they are usually detected incidentally while diagnosing and treating other malignancies. This paper reports a case of invasive ductal carcinoma (IDC) concomitant with NHL.

Presentation Of Case: A 35-year-old woman presented with simultaneous IDC in the left breast and NHL in a lymph node in the neck. The patient underwent a modified radical mastectomy for stage IIIA IDC and received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for stage I NHL.

Clinical Discussion: Treating BC and NHL remains challenging due to their significantly different management, the lack of guidelines for treating BC and lymphoma simultaneously, and uncertainty about whether synchronous tumors should be treated separately as distinct clinical entities or as one disease with treatment covering both. Therefore, the best approach continues to be focusing on the most biologically aggressive malignancies.

Conclusion: The enlargement of lymph nodes not in the lymphatic drainage of the primary tumor should be suspected of indicating multiple primary malignancies until proven otherwise. For patients with luminal-B BC, NHL chemotherapy can involve receiving the R-CHOP regimen, including doxorubicin and cyclophosphamide, which can help to mitigate BC.

Citing Articles

Two case reports of breast cancer combined with synchronous primary intrahepatic cholangiocarcinoma/mixed liver cancer.

Tan M, Luo L, Wang T, Zhang Z, Wei Y, Long C Medicine (Baltimore). 2024; 103(48):e40653.

PMID: 39612433 PMC: 11608741. DOI: 10.1097/MD.0000000000040653.

References
1.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

2.
Zhai C, Cai Y, Lou F, Liu Z, Xie J, Zhou X . Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China. J Cancer. 2018; 9(16):2795-2801. PMC: 6096360. DOI: 10.7150/jca.25482. View

3.
Subramanian C, Cotter 2nd M, Robertson E . Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis. Nat Med. 2001; 7(3):350-5. DOI: 10.1038/85499. View

4.
Prihantono , Faruk M . Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it?. Ann Med Surg (Lond). 2021; 70:102793. PMC: 8519754. DOI: 10.1016/j.amsu.2021.102793. View

5.
Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View